Évaluation du Virus de l'Hépatite B Dans les Essais Cliniques du Baricitinib Dans la Polyarthrite Rhumatoïde
RMD Open 2020;6:e001095
Although hepatitis B virus (HBV) reactivation was seen in patients with RA treated with DMARDs, including BARI, who had serology suggestive of prior infection, reactivation was transient even with continued BARI treatment and did not account for any clinically relevant AEs.Reactivation of HBV replication is a recognised complication in patients receiving biologic agents for RA, such as DMARDs. Limited data exist on prevalence of occult infection and the incidence of reactivation in RA patients t...